This is highly speculative because: Oral bioavailability differs between species Route of administration affects systemic exposure Species differences in peptide metabolism and clearance are unknown Current Practice Patterns Current practice patterns from unregulated sources typically involve: Subcutaneous injection: 0.25-0.5 mg once or twice daily, administered near injection sites for localized effects or abdominally for systemic distribution
Muscle preservation requires active attention Deeper weight loss creates risk of significant lean mass loss
Ive seen severe deficiencies among vegetarian patients with heart failure or extreme fatigue
Li Y, Glotfelty EJ, Karlsson T, Fortuno LV, Harvey BK, Greig NH (2021) The metabolite GLP-1 (936) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration
At 12 mg in Phase 2, every single participant (100%) lost at least 5% of body weight
The 2-AG Endocannabinoid Pipeline : L